Puma Biotechnology (PBYI) Finished Goods (2020 - 2026)
Puma Biotechnology (PBYI) posted Finished Goods of $767000.0 for Q1 2026, down 20.1% on a QoQ basis from $960000.0 in Q4 2025, and up 36.72% year-over-year from $561000.0 in Q1 2025.
Puma Biotechnology (PBYI) Finished Goods (2020 - 2026) Analysis & Trends
Puma Biotechnology's Finished Goods history runs 7 years deep, the most recent figure standing at $767000.0 for Q1 2026.
- Quarterly Finished Goods rose 36.72% year-over-year to $767000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $767000.0 (up 36.72% YoY) and the FY2025 annual result came in at $960000.0, up 22.61% from the prior year.
- Finished Goods was $767000.0 for Q1 2026 at Puma Biotechnology, down from $960000.0 in the prior quarter.
- Across five years, Finished Goods topped out at $1.6 million in Q1 2022 and bottomed at $186000.0 in Q4 2022.
- A 5-year average of $696000.0 and a median of $642000.0 in 2022 frame the typical range for Finished Goods.
- Annual changes were most pronounced in 2022 — Finished Goods tumbled 83.9% — and 2023, when it jumped 204.84%.
- Puma Biotechnology's Finished Goods stood at $186000.0 in 2022, then soared by 204.84% to $567000.0 in 2023, then surged by 38.1% to $783000.0 in 2024, then gained by 22.61% to $960000.0 in 2025, then dropped by 20.1% to $767000.0 in 2026.
- Business Quant data shows PBYI's Finished Goods at $767000.0 in Q1 2026, $960000.0 in Q4 2025, and $439000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Puma Biotechnology | 407.27 Mn | 368.99 Mn | 34.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 767,000.00 |
| Dec 31, 2025 | 960,000.00 |
| Sep 30, 2025 | 439,000.00 |
| Jun 30, 2025 | 762,000.00 |
| Mar 31, 2025 | 561,000.00 |
| Dec 31, 2024 | 783,000.00 |
| Sep 30, 2024 | 457,000.00 |
| Jun 30, 2024 | 663,000.00 |
| Mar 31, 2024 | 488,000.00 |
| Dec 31, 2023 | 567,000.00 |
| Sep 30, 2023 | 978,000.00 |
| Jun 30, 2023 | 618,000.00 |
| Mar 31, 2023 | 850,000.00 |
| Dec 31, 2022 | 186,000.00 |
| Sep 30, 2022 | 482,000.00 |
| Jun 30, 2022 | 642,000.00 |
| Mar 31, 2022 | 1.63 Mn |
| Dec 31, 2021 | 1.16 Mn |
| Dec 31, 2020 | 765,000.00 |